Clinical Trial

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-28.
Trial Details
NCT Number NCT07101588
Lead Sponsor Chinese PLA General Hospital
Collaborators: The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital
Conditions Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment 200 participants
Start Date 2025-01-01
Primary Completion 2028-01-01 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20